Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by Wino115on Feb 03, 2022 10:35pm
264 Views
Post# 34395869

Mea Culpa, strong start to year….wrong

Mea Culpa, strong start to year….wrong

I don't make too many short term price predictions. But if I do, I try to follow up.


I thought with the end of year swoon, which appeared to me to be a lot of tax loss mixed with stale investors and regular market profit takers after a relatively strong 2H performance, that we'd see a decent bounce back to that steady $3.50 holding level in Jan. We're a month in and haven't been close to that level.  As SPCEO often pointed out, the bull mkts old age was not going to help THTX and that seems to have been the case.  Notwithstanding the decent relative perf YTD, it's not really sprung back strongly like I thought it would.  


No news and mkt headwinds scuppered my price prediction.  Wrong on that one! Now on to fundamentals driving the price.  

<< Previous
Bullboard Posts
Next >>